Alliance for a Stronger FDA Webinar Summary: Dr. Paul Kluetz, Deputy Director of FDA's Oncology Center of Excellence

Tue, Jun 20, 2023 3:30PM

In a thought-provoking conversation with Jeff Allen from Friends of Cancer Research and Jon Retzlaff from the American Association for Cancer Research, Dr. Paul Kluetz, the FDA's Oncology Center of Excellence (OCE) Deputy Director, shared insights on the fast-paced world of cancer drug development and the OCE's vital role in it.

One key takeaway was the surge in oncology drug applications, especially in ground-breaking areas like cell and gene therapies. This increase in workload signals the need for more staff at the OCE to handle the growing complexity and volume of cancer treatments.

Dr. Kluetz also explained the role of innovative regulatory tools. The breakthrough therapy designation, for instance, allows the FDA to fast-track reviews for exceptionally promising treatments. This strategy is crucial in managing the flood of drug applications. Additionally, he discussed Project Orbis, which aims to align regulatory decisions across countries. This initiative isn't just about getting innovative therapies to patients around the globe quicker; it also helps improve multi-regional clinical trials by creating a more consistent treatment landscape worldwide.

The conversation also touched on the OCE's collaborations with other FDA centers, like the Center for Devices and Radiological Health (CDRH) and the Center for Biologics Evaluation and Research (CBER). These partnerships help the OCE evaluate oncology treatments more effectively, underlining the multifaceted nature of the Center's work.

In addition, Dr. Kluetz introduced a novel pilot project related to in vitro diagnostic tests. Aimed at increasing transparency around the performance characteristics of these tests, the initiative could lead to improved patient selection in real-world settings. Interestingly, this project opens its doors to participation not only from the usual sponsors but also academic research institutions, thereby fostering a broader range of perspectives.

Rounding up the discussion, Dr. Kluetz stressed the important role advisory committees play in the review process. Despite the challenges of assembling these committees due to strict conflict of interest rules, the OCE provides educational outreach to members, including FDA 101 webinars, to ensure they are well-versed in the regulatory landscape. He provided a nuanced perspective on the issue of voting during advisory meetings, suggesting its applicability could vary depending on the context. Despite recognizing the critiques, he pointed out the merit of voting in compelling committee members to establish solid rationales for their decisions. He concluded by saying that the committees' value extends beyond individual product decisions; they can also be an invaluable resource for addressing broader drug development challenges.